Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies

Area of Science:

• Oncology
• Epigenetics
• Cancer Metastasis

Background:

• Bone metastasis significantly impacts patient quality of life in advanced breast, prostate, and lung cancers.
• Reversible epigenetic alterations are increasingly recognized as key drivers of skeletal colonization by cancer cells.

Purpose of the Study:

• To review the mechanistic roles of epigenetic modifications in bone metastasis.
• To evaluate the therapeutic landscape of epigenetic therapies for bone metastases.
• To outline translational challenges in leveraging epigenetic science for treatment.

Main Methods:

• Review of current literature on epigenetic mechanisms in bone metastasis.
• Analysis of epigenetic alterations including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs.
• Evaluation of preclinical and clinical data on epigenetic drugs and novel therapeutic approaches.

Main Results:

• Epigenetic changes like promoter hypermethylation and global hypomethylation influence cancer cell plasticity and epithelial-to-mesenchymal transition (EMT).
• Histone modifiers and chromatin remodelers regulate bone tropism and the metastatic niche.
• Non-coding RNAs modulate the bone microenvironment via the RANKL/OPG axis.
• Epigenetic therapies, including DNA methyltransferase and histone deacetylase inhibitors, show promise.
• Targeted inhibitors and novel approaches like epigenome editing are advancing in clinical trials.

Conclusions:

• Epigenetic modulation is a critical factor in the bone metastasis cascade.
• Epigenetic therapies represent a promising avenue for precision oncology in treating bone metastases.
• Overcoming translational challenges is essential for the clinical success of epigenetic strategies.